NextPlat Changes the Date of its 2024 Financial Results Report and Investor Conference Call to Monday, March 24, 2025
COCONUT GROVE, Fla., March 13, 2025 /PRNewswire/ — NextPlat Corp (NASDAQ: NXPL, NXPLW) (“NextPlat” or the “Company”), a global e-Commerce... Read more.
BlackRock USD Institutional Digital Liquidity Fund (BUIDL), Tokenized By Securitize, Surpasses $1B in AUM
Achieves Industry Milestone, Cementing Role as Tokenization Leader Accelerating Digital Asset Usage Among Institutions MIAMI, March 13, 2025 /PRNewswire/ — Securitize... Read more.
PREFORMED LINE PRODUCTS ANNOUNCES FOURTH QUARTER 2024 FINANCIAL RESULTS
CLEVELAND, March 13, 2025 /PRNewswire/ — Preformed Line Products Company (NASDAQ: PLPC) today reported financial results for its fourth quarter of 2024 and... Read more.
ARK INVESTMENT MANAGEMENT LLC ANNOUNCES PRIMARY LISTING VENUE CHANGES FOR ARK INNOVATION ETF (ARKK), ARK NEXT GENERATION INTERNET ETF (ARKW), AND ARK FINTECH INNOVATION ETF (ARKF)
ST. PETERSBURG, Fla., March 10, 2025 /PRNewswire/ — ARK Investment Management LLC (“ARK”) announced today plans to change the primary listing venue... Read more.
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screened Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several... Read more.
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
Positive topline results from an interim analysis of the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of farabursen (RGLS8429)... Read more.
Vuzix Reports 4Q and Full Year 2024 Financial Results
ROCHESTER, N.Y., March 13, 2025 /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI) (“Vuzix” or the “Company”), a leading supplier of... Read more.
Docusign Announces Fourth Quarter and Fiscal Year 2025 Financial Results
SAN FRANCISCO, March 13, 2025 /PRNewswire/ — Docusign, Inc. (NASDAQ: DOCU) today announced results for its fourth quarter and fiscal year ended January 31,... Read more.
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with... Read more.
AAR to announce third quarter fiscal year 2025 results on March 27, 2025
WOOD DALE, Ill., March 13, 2025 /PRNewswire/ — AAR CORP. (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs,... Read more.